21,448 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Tri Ri Asset Management Corp

Tri Ri Asset Management Corp purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 21,448 shares of the biotechnology company’s stock, valued at approximately $7,686,000. United Therapeutics makes up 8.6% of Tri Ri Asset Management Corp’s portfolio, making the stock its 2nd largest position.

Several other large investors have also made changes to their positions in UTHR. ClariVest Asset Management LLC boosted its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new position in United Therapeutics in the 2nd quarter valued at approximately $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the 2nd quarter valued at approximately $33,000. USA Financial Formulas bought a new position in United Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, Brooklyn Investment Group bought a new position in United Therapeutics in the 3rd quarter valued at approximately $33,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Bank of America dropped their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $370.86.

Insiders Place Their Bets

In other news, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the transaction, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,227 shares of company stock worth $47,398,820. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

NASDAQ UTHR traded up $1.13 during mid-day trading on Thursday, reaching $378.13. 323,202 shares of the stock were exchanged, compared to its average volume of 457,791. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The stock has a 50 day simple moving average of $366.18 and a 200-day simple moving average of $333.84. The stock has a market cap of $16.88 billion, a P/E ratio of 16.61, a P/E/G ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the company posted $5.38 earnings per share. Sell-side analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.